CONTRASTING US PATIENTS WITH A FILL VERSUS A PRESCRIPTION FOR ALIROCUMAB: EARLY EVIDENCE FROM ADMINISTRATIVE CLAIMS, EMR AND LAB DATA
| Autor: | Velichka Valcheva, Katherine Gorcyca, Şerban R. Iorga, Chakkarin Burudpakdee, Eli M. Roth, Joseph Elassal |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
business.industry Atherosclerotic cardiovascular disease nutritional and metabolic diseases Familial hypercholesterolemia medicine.disease Adjunct Administrative claims medicine lipids (amino acids peptides and proteins) Medical prescription Cardiology and Cardiovascular Medicine Intensive care medicine business Alirocumab |
| Zdroj: | Journal of the American College of Cardiology. 69:1713 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/s0735-1097(17)35102-1 |
| Popis: | Background: Alirocumab (ALI), a PCSK9-inhibitor, was approved in 7/2015, as an adjunct to diet and maximally tolerated statins for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, requiring additional lowering of LDL-C. We described the |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|